uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Evaluation of peptide-receptor radionuclide therapy in breast cancer and neuroblastoma, in combination with the radio-sensitizing drug VIP-116
Uppsala University, Disciplinary Domain of Science and Technology, Biology, Biology Education Centre.
2018 (English)Independent thesis Advanced level (professional degree), 20 credits / 30 HE creditsStudent thesis
Abstract [en]

Cancer being one of the leading causes of death globally, raises an international fight to defeat and finally conquer cancer. It represents more than 200 different diseases that individually have varying symptoms and treatments. The p53-pathway is of great interest as it has shown to be crucial in the formation of cancerous cells. One method is to use peptide-receptor radionuclide therapy to target somatostatin receptors that are overexpressed on cancer cells. The somatostatin-receptor analogue DOTATATE is a peptide that targets these receptors. In this project, the radionuclide (177Lu) is attached to DOTATATE to achieve a localized radiation effect targeting only the tumour cells and not surrounding tissue. In combination with the radiation-sensitizing drug VIP-116, the effect is supposedly enhanced. The findings of this project conclude the specific targeting of 177Lu-DOTATATE and the potential of VIP-116 to act as a radiosensitizer. The combination of both components works more efficiently on some cell lines than others, which emphasizes the need for tailored cancer therapies. 

Place, publisher, year, edition, pages
2018.
Series
UPTEC X ; 18 030
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-361523OAI: oai:DiVA.org:uu-361523DiVA, id: diva2:1250830
Educational program
Molecular Biotechnology Engineering Programme
Supervisors
Examiners
Available from: 2018-09-25 Created: 2018-09-25 Last updated: 2018-09-25Bibliographically approved

Open Access in DiVA

The full text will be freely available from 2021-09-25 00:00
Available from 2021-09-25 00:00

By organisation
Biology Education Centre
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 106 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf